Spike S1 (B.1.1.7, Alpha Variant) (SARS-CoV-2) : ACE2 Inhibitor Screening Colorimetric Assay Kit

The pandemic coronavirus disease 2019 (COVID-19) is caused by Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) . As a first step of the viral replication strategy, the virus attaches to the host cell surface before entering the cell. The Spike protein of the SARS-CoV-2 recognizes and attaches to the Angiotensin-Converting Enzyme 2 (ACE2) receptor found on the surface of type I and II pneumocytes, endothelial cells, and ciliated bronchial epithelial cells. It has been widely suggested that active as well as passive immunizations targeting the interaction between the Spike protein of SARS-CoV-2 and ACE2 offer promising protection against the viral infection. Reports showed that a mutant strain first identified in the UK (B1.1.7) exhibits higher transmissibility and infectivity. The B.1.1.7 variant contains multiple mutations, including several in the Spike protein that leads to higher infectivity rates than the wild-type virus. The S1 subunit (a.a. 14-685) of the Spike protein includes the Receptor Binding Domain (RBD) region (a.a. 319-591) that is responsible for binding to the ACE2 receptor on target cells.  Mutations outside of the RBD in the S1 subunit of spike are important for influencing the immunogenicity, conformation, and flexibility of the spike protein.  Investigations on the effects of mutations on viral replication and pathogenesis will be critical for developing effective strategies for vaccines and antibody therapies against COVID-19.

Catalog #NameAmountStorageSpike S1 (del_HV69-70, del_Y144, N501Y, A570D, D614G, P681H), His-tag (SARS-CoV-2) 10 µg-80°C100665ACE2, His-Avi-Tag, Biotin-labeled HiP™5 µg-80°C79742Streptavidin-HRP10 µl+4°C793113x Immuno Buffer 150 ml-20°C79728Blocking Buffer 250 ml+4°C79651Colorimetric HRP substrate10 ml+4°C79964Transparent 96-well microplate1Room Temp